News
APMD
26.23
-2.13%
-0.57
Apnimed: What We Know Heading Into The Feb PDUFA
Seeking Alpha · 1d ago
Apnimed: Buy Rating Reiterated on Strong Oxnimbi OSA Profile and Unchanged $50 Price Target
TipRanks · 2d ago
Apnimed Swings To Q2 Profit, Eyes February 2027 FDA Decision On AD109 In Obstructive Sleep Apnea
NASDAQ · 3d ago
Apnimed, Inc. reports Q2 results
Seeking Alpha · 3d ago
Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M
Benzinga · 3d ago
*Apnimed 2Q Net $125.9M >APMD
Dow Jones · 3d ago
Press Release: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 3d ago
Press Release: Apnimed Reports Second Quarter -2-
Dow Jones · 3d ago
Weekly Report: what happened at APMD last week (0831-0904)?
Weekly Report · 5d ago
Weekly Report: what happened at APMD last week (0824-0828)?
Weekly Report · 08/31 10:41
Wall Street Analysts Are Bullish on Top NA Picks
TipRanks · 08/30 13:20
Apnimed rises on Street initiations following IPO
Seeking Alpha · 08/25 15:31
Apnimed Price Target Announced at $50.00/Share by LifeSci Capital
Dow Jones · 08/25 15:28
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50
Benzinga · 08/25 15:18
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 08/25 12:10
Apnimed Price Target Announced at $60.00/Share by Cantor Fitzgerald
Dow Jones · 08/25 11:14
Apnimed Initiated at Outperform by Evercore ISI Group
Dow Jones · 08/25 11:04
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60
Benzinga · 08/25 11:04
Apnimed Initiated at Buy by B of A Securities
Dow Jones · 08/25 10:59
Apnimed Price Target Announced at $41.00/Share by B of A Securities
Dow Jones · 08/25 10:59
More
Webull provides a variety of real-time APMD stock news. You can receive the latest news about Apnimed through multiple platforms. This information may help you make smarter investment decisions.
About APMD
Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.